Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study.
about
Kras(G12D) and Nkx2-1 haploinsufficiency induce mucinous adenocarcinoma of the lungFirst-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancerConsidering Exosomal miR-21 as a Biomarker for CancerMolecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for MolecularK-Ras Mutations in Non-Small-Cell Lung Cancer: Prognostic and Predictive ValuePooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy.Molecular pathology of lung cancer: key to personalized medicine.Personalized treatment of advanced non-small-cell lung cancer in routine clinical practiceA comprehensive survey of Ras mutations in cancer.Loss of phosphatase and tensin homolog expression correlates with clinicopathological features of non-small cell lung cancer patients and its impact on survival: A systematic review and meta-analysis.Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for MolecularEGFR expression and survival in patients given cetuximab and chemoradiation for stage III non-small cell lung cancer: a secondary analysis of RTOG 0324.Identification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking status.Personalized medicine and cancer.A network module-based method for identifying cancer prognostic signaturesPrognostic and predictive value of KRAS mutations in advanced non-small cell lung cancer.Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non-small cell lung cancer.Diagnostic value of microRNA-21 in the diagnosis of lung cancer: evidence from a meta-analysis involving 11 studies.EGFR-directed monoclonal antibodies in non-small cell lung cancer: how to predict efficacy?Cetuximab in non-small-cell lung cancerPhosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin (PI3K-Akt-mTOR) signaling pathway in non-small cell lung cancerDefining the role of tyrosine kinase inhibitors in early stage non-small cell lung cancer.Genomic classification of the RAS network identifies a personalized treatment strategy for lung cancerIncreasing the clinical efficacy of NK and antibody-mediated cancer immunotherapy: potential predictors of successful clinical outcome based on observations in high-risk neuroblastoma.Biomarkers that currently affect clinical practice: EGFR, ALK, MET, KRASDesign of a phase III clinical trial with prospective biomarker validation: SWOG S0819Cetuximab and biomarkers in non-small-cell lung carcinomaMicroRNAs level as an initial screening method for early-stage lung cancer: a bivariate diagnostic random-effects meta-analysis.Meta-analysis of human lung cancer microRNA expression profiling studies comparing cancer tissues with normal tissues.Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy.Molecularly targeted therapies for advanced or metastatic non-small-cell lung carcinomaPlatelet count predicts prognosis in operable non-small cell lung cancer.Predicting Survival in Patients with Advanced Non-squamous Non-small Cell Lung Cancer: Validating the Extent of MetastasisEGFR inhibition in non-small cell lung cancer: current evidence and future directionsEGFR protein expression using a specific intracellular domain antibody and PTEN and clinical outcomes in squamous cell lung cancer patients with EGFR-tyrosine kinase inhibitor therapy.Emerging options for the management of non-small cell lung cancer.Differences in EGFR and KRAS mutation spectra in lung adenocarcinoma of never and heavy smokers.Autophagy sensitivity of neuroendocrine lung tumor cellsOncolytic reovirus in combination with chemotherapy in metastatic or recurrent non-small cell lung cancer patients with KRAS-activated tumors.Low-frequency KRAS mutations are prevalent in lung adenocarcinomas
P2860
Q24303485-E007A475-FD45-42F8-A1D5-907A6CACD72CQ26471909-23008D6D-1178-4863-B86B-943492D6D127Q26752550-9106DD51-9D85-4039-A088-105FD219FF69Q26828860-98BDCB57-5F22-42AA-A777-1BBDCD3E3D62Q26829425-6CFF8156-91B5-47F7-AE92-A124BE03FFBBQ27313799-B5EBDB98-BF74-4C0F-B8FC-B605AFAA3EC2Q27691299-45F918EF-EB78-4987-9300-35AB4B8F6E2CQ28075800-E5EC5265-8C57-4727-A87A-A2DA802CC14AQ30416821-15967889-FE1E-41FD-B901-AD5A354F4583Q33633647-04707E88-A835-4A21-8410-93587E3869A1Q34159011-FC1DAA5E-22C5-4D81-B2AD-27DF2C0491FAQ34216725-6FD29779-6E5C-4C4C-8223-7D823D3EF66AQ34328665-3E7B4A54-3D09-4809-9F85-E84636962EF0Q34608577-718D05A0-A134-4910-8D0B-5217C716908FQ34646243-EFAFBEDE-1C11-48FF-873C-8A58FFE8CEB6Q34749852-EEB12797-693A-4F9A-83CF-5B8F21B383F9Q35081379-E72E80FF-A4D5-42B2-8561-1CDFB8747817Q35177139-C7580846-5563-4929-A2A5-E24B1536D82BQ35200322-23E5F920-43A4-46E7-BE4B-2428B5858A06Q35200393-F9330A4A-47AD-4FA5-AD1B-7EFFF5212056Q35256618-C4D28F47-657F-4D87-AB09-BA43EF723DABQ35631635-C507C426-241D-4B17-A527-E551A514576AQ35670290-CD570AD7-6598-4BB1-AE41-2C83A28FF9E7Q35963440-C6E40FD0-7B65-4202-9787-C4E2CD7418A7Q36040606-D3308CA5-5BE2-4579-A284-0A2DA75B4BE9Q36133455-5AF61A33-B61F-4722-BADB-B376094A4ED7Q36171281-F14470F6-26BB-4C28-BD6D-3C1DD803BB9CQ36182680-1B3229F4-2F24-420D-A9DF-D94BF1A2215BQ36411401-AC630657-0573-45C1-96AB-38593CBFFFF9Q36557569-2BBAA0EC-7A18-4622-89D4-AFC2E870F6DBQ36859958-D546D8EA-C2FE-47EE-BA8B-B2157DBAE513Q36900438-713A8C08-9151-4948-80F5-2B5077699024Q37011155-4A0A3F47-1E7F-4137-9FBC-B76B491CDE7CQ37180302-0B2025E7-DFEE-4829-B99E-0055E8172CF4Q37204247-7C49F149-9E39-47AB-A1F3-3923FD1AF781Q37269316-9AADCC62-CCF6-4DDE-A997-40A5498098FCQ37269571-2CBD13B4-C12C-4F3E-834F-9BF07CDEBE25Q37325416-1689732C-8F37-458D-B852-028D78889683Q37347236-CACD0CE9-EBFD-474B-A0F3-292D0842C241Q37375834-1C31F0B9-B1BD-4FFE-B780-852273FCB2E6
P2860
Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Molecular biomarkers in non-sm ...... a from the phase 3 FLEX study.
@ast
Molecular biomarkers in non-sm ...... a from the phase 3 FLEX study.
@en
type
label
Molecular biomarkers in non-sm ...... a from the phase 3 FLEX study.
@ast
Molecular biomarkers in non-sm ...... a from the phase 3 FLEX study.
@en
prefLabel
Molecular biomarkers in non-sm ...... a from the phase 3 FLEX study.
@ast
Molecular biomarkers in non-sm ...... a from the phase 3 FLEX study.
@en
P2093
P1433
P1476
Molecular biomarkers in non-sm ...... a from the phase 3 FLEX study.
@en
P2093
Armin Schueler
Carlos Barrios
Chih-Teng Yu
Christopher Stroh
Corinna Eschbach
Cornelius Kortsik
Ilhan Celik
Jae-Kyung Roh
Joachim von Pawel
Jose R Pereira
P304
P356
10.1016/S1470-2045(11)70189-9
P577
2011-07-22T00:00:00Z